Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Next Previous
X
Search
Trial Profile

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Paclitaxel (Primary) ; Abciximab; Eptifibatide; Heparin; Tirofiban
  • Indications Coronary artery restenosis; Myocardial infarction; Stent thrombosis; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HORIZONS-AMI; HORIZONS-AMI CMRI

    • Most Recent Events

    • 07 Nov 2022 Results of pooled subgroup analysis (n=15254) assessing efficacy of bivalirudin versus heparin in patients with STEMI undergoing PCI from BRIGHT, EUROMAX, HEAT-PPCI, HORIZONS-AMI, MATRIX, and VALIDATE-SWEDEHEART studies, presented at the American Heart Association Scientific Sessions 2022.
    • 01 Dec 2017 Results of age-based subgroup analysis assessing the effect of bivalirudin versus heparin using 30-day pooled data (n=5800) from the two large randomized trials (EUROMAX and HORIZONS-AMI), published in the American Heart Journal.
    • 29 Mar 2017 Results of comparison of outcomes and prognostic factor in patients with versus without newly diagnosed daibetes mellitus published in the American Journal of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top